|
Verici Dx PLC on Tuesday reported further data from a clinical validation study evaluating Tuteva, the company's post-transplant blood test focused on acute rejection.
The Tennessee-based clinical diagnostics company said the data demonstrated a positive predictive value of 60% and a negative predictive value of 80% for Tuteva. It said this confirmed a strong performance in the detection of acute rejection following a kidney transplant.
Shares in Verici Dx were down 25% at 20.00 pence on Tuesday morning in London, following the announcement. The stock is down 75% over the past 12 months.
‘These clinically important results position Tuteva for an on-schedule commercial launch later this year,’ the company said.
The trial continues for new validations of other pre- and post-transplant tests.
Chief Executive Sara Barrington said: ‘I'm delighted that the data shows that our underlying technology has the potential to be clinically groundbreaking, particularly as we focus on commercial launch later this year with the goal of making this much needed test available to all kidney transplant patients, so that an earlier clinical diagnosis can better inform their medical management.’
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
